Group items matching

in title, tags, annotations or url

Online pharmacies have to operate from bricks & mortar premises that are registered with the General Pharmaceutical Council, but recent cases show that, in reality, the practices of online pharmacies are often very different to other pharmacies, and the regulation of online pharmacies is also different - and evolving as issues arise. For a start, the General Pharmaceutical Council (GPhC) is only one of the regulators taking an interest in online pharmacy services. Other regulators include the Medicines and Healthcare products Regulatory Agency (MHRA) which enforces the advertising and promotion of medicines, and the Care Quality Commission (CQC) which regulates prescribing services. The different regulation of online pharmacies is attributable to the higher risk to patients and the public from medicines bought online. These risks often arise from a combination of patients who do not tell the truth in order to obtain medicines and the nature of a transaction in which a pharmacist does not see patients face-to-face. "The GPhC has strong enforcement powers that it uses when it considers its premises standards have not complied with." However, there are also things that go wrong because pharmacists have simply failed to act professionally or take sufficient care, as well as cases where things have gone wrong through misfortune.

When you visit a hospital, one of the last things that come to mind is worrying about legal aspects and what rights you might have - or lack. But these issues and your understanding of them are more important than ever. Knowing exactly what hospitals can legally and cannot do to you is an essential part of ensuring your protection as a patient when going in for care. In this blog post, we'll break down the legal details behind being treated at a hospital so that you can feel more confident when making healthcare decisions. Let's dive into the legal aspect of visiting a hospital, outline what hospitals can and cannot do to us, discover our rights as patients, and review any other considerations worth keeping in mind! OVERVIEW OF MEDICAL MALPRACTICE LAW AND HOW IT RELATES TO VISITING A HOSPITAL When going to a hospital, concerned patients and their families should be aware of the legal risks posed in medical malpractice cases. These potential issues can have life-altering consequences if misdiagnoses, wrong medication administration, or improper treatment occurs. Now, whether you seek damages for your injuries at Staten Island University Hospital or in a different hospital in your hometown, it is important for visitors to understand that the law has set forth regulations regarding acceptable standards of care expected by our nation's hospitals. Those regulations can include procedures of qualified professionals that protect patients from financial exploitation and physical or emotional distress caused by medical negligence. Understanding how this information applies to you will help you protect yourself legally if your rights are violated while visiting a hospital.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

Kent based N.B. Pharmacy has been sold to first-time buyers, Venkat and Preeti Adama, from Essex for an undisclosed price. N.B. Pharmacy is a standard hours community pharmacy that dispenses an average of 6,393 items per month. The business has been owned by Nirmal Bajaria for 39 years and was recently brought to market to allow him to pursue a well-earned retirement. Following a confidential sales process with Christie & Co, it has been purchased by first-time buyers, Venkat and Preeti Adama, from Essex. Nirmal Bajaria, former owner of N.B. Pharmacy, comments, "Having run the pharmacy for around 39 years, it was a difficult decision to put the business up for sale. I was very pleased with the high number of viewers and feel delighted that a young family bought my pharmacy."

British pharmaceutical giant GSK said on Saturday (April 15) its oral antibiotic drug to treat uncomplicated urinary tract infections (uUTI) in female adults and adolescents met the main goals in late-stage trials. The drug, gepotidacin, in phase III trials, met its primary goals of being on a par or better than nitrofurantoin, the current standard of care for the treatment of uUTIs, the company said. GSK plans to submit results of the trials to the United States Food and Drug Administration for review later in the second quarter. The drug, if approved, could become the first new type of antibiotic, which is critically important for countering drug-resistant infections, to treat uUTIs in 20 years, the company said. "Gepotidacin, if approved, will offer a much-needed additional oral treatment option for patients at risk of treatment failure associated with resistance or recurrence of uUTI," Chris Corsico, senior vice president of development at GSK, said.

Pharmacies are the lifeblood of community healthcare, being a vital pathway to care and support in every borough of the UK. There are 11,600 pharmacies across the country, amongst which yours stands proudly. Pharmacies obviously have a duty of care to their patients and customers, and rigorous safety practices surrounding the safe storage and dispensation of medicine - but that duty of care also extends to fellow staff. This is to say that health and safety is a paramount concern for any pharmacy or pharmacist, and that great care should always be taken to uphold the highest possible standards with regard to health and safety. With this in mind, what follows is a refresher on some of the key hazards that could give way to workplace injury in your pharmacy - and how to mitigate the risk of injury. Biological Hazards Biological hazards are ever-present, and prescient in the aftermath of the coronavirus pandemic. Though the COVID-19 virus was eventually shown not to be particularly resilient on surfaces, good practice was still to regularly disinfect surfaces and handles where possible - something which should still be a part of regular routine in your pharmacy. Likewise, face masks are a solid way to reduce the risk of infection or contamination, particularly where the handing over of biological samples is concerned.

A BBC investigation has found 20 UK online pharmacies selling prescription-only medicines without adhering to the regulatory standards, such as checking for GP approval or patient's medical records. The news organisation was able to purchase over 1,600 restricted pills, including anti-anxiety drug, painkiller and sleeping medication, from these regulated online pharmacies easily by providing false information. However, the report didn't mention the names of the drugs as "they can be dangerous when taken without medical guidance." Some pharmacies were also found selling high-risk and potentially addictive medicines, including benzodiazepines and antidepressants, based on online questionnaires and did not require further checks. The General Pharmaceutical Council (GPhC), which regulate online pharmacies in the UK, states that selling and supplying medicines at a distance brings "different risks which need to be appropriately managed to protect patient safety."

The Royal Pharmaceutical Society's (RPS) second roundtable on workforce wellbeing resulted in a series of collaborative actions to address pharmacy professionals' mental health and wellbeing challenges. The roundtable brought together key stakeholders from the pharmacy sector, including organisations like the General Pharmaceutical Council (GPhC), Community Pharmacy England (CPE), the National Pharmacy Association (NPA), and the profession's independent charity Pharmacist Support (PS). A report detailing the outcomes of the meeting was published on Friday, highlighting the key areas of discussion and the agreed-upon actions by the participants. During the roundtable, participants discussed the importance of understanding the workforce demographics, both nationally and locally, and using data to address wellbeing issues effectively. They also emphasised the need for using supportive standards set by the General Pharmaceutical Council (GPhC) and the Care Quality Commission (CQC) quality statement to support and empower pharmacists' wellbeing positively.

American pharmaceutical giant Pfizer has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for its medication Etrasimod, marketed as Velsipity, used to treat people with moderately to severely active ulcerative colitis. Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the lining of the large intestine (colon) and rectum. The approved recommended dose for Velsipity is one 2 mg tablet to be taken once daily. For the first three days, it is advised to take the medication with food, and subsequently, it can be taken daily either with or without food. According to the regulator, the approval of the medication is based on evidence from two clinical studies, which showed that 26 per cent of patients taking etrasimod achieved clinical remission after 12 weeks of treatment compared with 11 per cent of those receiving placebo. The studies included more than 740 patients aged 16 years and over for whom standard treatment or other treatments did not work well enough or could not be used.

The Professional Pharmacists Association (PDA) has demanded efforts to secure greater support and recognition for community pharmacists from governmental bodies. In its written evidence provided to the Health and Social Care select committee's pharmacy inquiry, the PDA raised concerns about the well-being of pharmacists, specifically for those who belong to minority ethnic groups and race and are subjected to bullying, harassment, and ill-treatment. The association highlighted issues in the workplace that impact pharmacists' health and well-being, including chronic understaffing, sub-standard working environments, an absence of protected training time, and experiences of racism, violence, and abuse. Parallel to the PDA's advocacy, the Royal Pharmaceutical Society (RPS) is intensifying calls for prioritising workforce wellbeing within the pharmacy domain. Stressing the pivotal role of workforce retention in addressing current challenges, RPS emphasises the need for robust support mechanisms and equitable access to mental health services.

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised the public to exercise caution when buying anti-choking devices online, ensuring these products are purchased from reputable sellers. As estimated by the regulator, more than 10,000 counterfeit or unbranded anti-choking devices have been purchased by the public within the last two years through listings on online marketplaces such as Amazon and eBay, as well as drop-shipping websites. People are cautioned that the use of such products poses a substantial risk of failure in clearing blockages and could exacerbate the situation by pushing obstructions further down into the airway passage. Dr Alison Cave, MHRA Chief Safety Officer, said: "Buying anti-choking devices that do not have a valid UKCA or CE mark increases the risk of receiving a product which does not include appropriate instructions and is either fake or does not meet the UK's regulatory requirements. "These products do not meet our strict quality standards and may put your health and safety at significant risk by failing to resolve or even worsening choking incidents."

QuickBooks Online offers convenient credit card processing for businesses, but navigating the associated fees can be confusing. Understanding the fee structure, influencing factors, and minimization strategies empowers you to make informed choices about using Quickbooks Online Credit Card. The optimal choice depends on your unique transaction volume, processing methods, budget, and industry risks. Consider exploring alternative processors, comparing features, and evaluating customer reviews before committing. Standard Payment Fees: QuickBooks charges per-transaction fees based on processing methods and card networks: Invoicing & Quick Requests: 2.99% for Visa, Mastercard, Discover, and American Express. Card Reader (swiped): 2.5% for the same cards. Keyed-in Payments: 3.5% for manual card entry (generally the highest rate). Digital Wallets: Same rates as invoices for Apple Pay and Google Pay. Additional Fees: Instant Deposits: 1.75% on top of standard rates for faster access to funds (ideal for cash flow needs). Payment Dispute Protection: 0.99% - 1.99% for added security against chargebacks (useful for high-risk industries).

QuickBooks simplifies accepting credit cards in your business, but understanding the associated fees is crucial for informed financial decisions. This guide provides an overview of QuickBooks credit card Online and Desktop fee structures, highlighting key considerations and strategies for minimizing costs. QuickBooks Online: Standard Fees: Invoicing & Quick Requests: 2.99% per transaction for major cards. Card Reader (swiped): 2.5%. Keyed-in Payments: 3.5%. Digital Wallets: Same as invoices. Additional Fees: Instant Deposits: 1.75% on top of standard fees. Payment Dispute Protection: 0.99% - 1.99%. Minimizing Costs: Encourage swiped payments. Limit keyed-in entries. Explore higher-volume tiers for discounts. Compared with other processors. Consider passing fees to customers (legally). Additional Considerations: Interchange Fees: These fees set by card networks are not controlled by QuickBooks and can vary by card type and industry. Statement Fees: Some merchant service providers charge monthly statement fees. Chargeback Fees: Fees incurred if a customer disputes a transaction. Integration: Consider how the processing solution integrates with your accounting software. Security: Choose a processor with robust security measures. Customer Support: Reliable support is crucial for resolving issues.

QuickBooks credit card processing fees may seem like a confusing masked ball, but understanding the players, the dance steps, and the hidden lingo empowers you to navigate with grace. But like any convenience, it comes with a cost in the form of processing fees. This guide will equip you with the knowledge to understand, decipher, and even minimize your QuickBooks credit card processing fees. By comparing, negotiating, and optimizing, you can control the financial rhythm and ensure your business enjoys a profitable performance, not a fiscal foxtrot disaster. Because the Picture this you, a savvy entrepreneur, enter the glittering realm of QuickBooks, eager to accept credit cards and watch your business flourish. But lurking within this alluring landscape lies a hidden threat the labyrinth of QuickBooks credit card Processing fees. Fear not, for like a seasoned detective,you can unveil their secrets and navigate this financial maze with confidence. So, enter the QuickBooks credit card labyrinth with confidence, dear entrepreneur, and dance your way to success, leaving the high fees and hidden charges behind. Because of the QuickBooks credit card labyrinth.

QuickBooks Payments simplifies accepting credit cards for your business, but understanding the associated fees is crucial for making informed financial decisions. This guide unravels the different types of QuickBooks credit card processing fees, how they're calculated, and potential strategies for minimizing them.By understanding the fee structure, influencing factors, and minimization strategies, you can make informed decisions about QuickBooks Payments for your business. Remember, the optimal choice depends on your unique transaction volume, processing methods, and budget considerations. Consider exploring alternative processors, comparing features, and evaluating customer reviews before committing. Understanding the Fee Structure: QuickBooks charges fees based on the method used to process the payment and your chosen plan. Here's a breakdown: Standard Payment Fees: Invoicing & Quick Requests: 2.99% per transaction for Visa, Mastercard, Discover, and American Express. Card Reader (Swiped): 2.5% per transaction for the same cards. Keyed-in Payments: 3.5% per transaction for manual card entry. Digital Wallets: Same rates as invoices for Apple Pay and Google Pay. Additional Fees: Instant Deposits: 1.75% on top of standard rates for faster access to funds. Payment Dispute Protection: 0.99% - 1.99% for added security against chargebacks.

After receiving approval from the National Institute for Health and Care Excellence (NICE), the NHS is preparing to roll out a new combination treatment for brain tumours in children and young people in England. Dabrafenib with trametinib would be the first ever targeted treatment for children (aged 1-17) with gliomas that have a specific genetic mutation, the health service said. The treatment, which can be taken at home, has been found to slow the progression of the disease by over threefold compared to standard chemotherapy in children with low-grade gliomas that have a BRAF V600E mutation. Clinical trials have shown that it causes fewer side-effects than chemotherapy. NICE approved the combination treatment on Wednesday 24 April. It will be available on the NHS in the coming months.

Women accounted for 62 per cent of GPhC registrants in 2019, according to the Royal Pharmaceutical Society. Despite representing the majority of pharmacists in the UK, only 2 per cent of women are pharmacy business owners compared with 13 per cent of men. Also, the majority of senior pharmacy leadership positions are held by men, with research showing that only 36 per cent of senior pharmacy leaders are women. Sobha Sharma Kandel, superintendent pharmacist and co-owner of Neem Tree Pharmacy, Abbey Wood, London, quoted these statistics while shedding light on the representation of female leaders in the field of pharmacy. So, what is stopping women from reaching leadership positions in the profession? According to Sobha, the barriers hindering female pharmacists from attaining leadership positions include: Gender Bias and Stereotypes Lack of Representation and Role Models Glass Ceiling and Double Standards Work-Life Balance Challenges Imposter Syndrome Unequal Access to Opportunities Negotiation and Advocacy Challenges "There also continue to be gender and ethnicity pay gaps affecting women in pharmacy," said Sobha, who has been advocating for women in pharmacy by being a part of the Female Pharmacy Leaders Network.

Medipharmacy has been bought out by PI-Gen Pharma Limited, an arm of the independent pharmacy group Enimed, for a total of £7.1 million, after the business entered into administration. In a report published on Companies House on January 30, administrators at FRP confirmed that the transaction was completed on 18 January, with PI-Gen beating five other bidders to acquire the insolvent NHS pharmacy chain. The report added that PI-Gen submitted a cash offer of non-refundable £500k for Medipharmacy's goodwill, £2.1m for its freehold properties, and a further amount for its fixtures and fittings, motor vehicles and stock. An FRP spokesperson told The Standard that Medipharmacy, which operated a chain of 25 NHS community pharmacies across London, Kent, Surrey and West Sussex, had faced increasing cashflow challenges in recent months. According to the administrators' report, Medipharmacy's revenues had grown exponentially from £27.9m in 2022 to £69m in 2023 but didn't deliver corresponding improvements in profitability.

Wednesbury Pharmacy in Sandwell, West Midlands has been purchased by Sukh Gill of Sodaskill Limited who already owns a community pharmacy in the area, Specialist business property adviser, Christie & Co, announced on Thursday (1st January) Located in the Friar Park area of Wednesbury, this pharmacy dispenses an average of 7,600 items per month and follows standard opening hours. It was owned by Enimed Limited for over five years before it was brought to market last year. The ownership of the business was changed to Gill, who already owns Friar Park Chemist just a few doors up the road, following a confidential 'off-market' sales process at Christie & Co. Carl Steer, Director - Medical at Christie & Co, said, "It is always pleasing to complete a sale, but when you have been able to perform to the brief a client dictates, all the better.

The General Pharmaceutical Council (GPhC) has promoted Louise Edwards to the position of Chief Strategy Officer and Deputy Registrar. Louise is currently the Director of Regulation and Digital Transformation at the Electoral Commission, responsible for the organisation's regulatory work and digital, data, technology and facilities infrastructure. This includes funding and spending at elections and referendums, registering political parties, enforcement work, and data and information management. Louise will take over Mark Voce, the GPhC's current Chief Strategy Officer and Deputy Registrar, who is retiring early in July 2024. Louise said: "Pharmacy services are at the heart of health care for many people. Having effective regulation and standards in place can transform and give confidence in the quality of care that people receive.

The General Pharmaceutical Council (GPhC) has produced a new resource to support pharmacists and pharmacy technicians who are providing pharmacy services to children and young people with gender incongruence or dysphoria. It emphasises that pharmacy teams providing such services need to adhere to the standard process of clinical assessment and care provision they have been trained to take as healthcare professionals. The starting point is that pharmacy professionals must provide compassionate, inclusive and person-centred care, within the current relevant legal and regulatory context. "It's essential that all patients have access to appropriate, high-quality and respectful healthcare, free from discrimination or bias," the GPhC noted